Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
Rev. Inst. Med. Trop ; 18(1)jun. 2023.
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1449259

RESUMO

Las vacunas previenen millones de muertes cada año y su eficacia y seguridad han sido ampliamente establecidas. En términos económicos, la vacunación es una de las intervenciones sanitarias más costo efectivas, generando un importante ahorro y crecimiento económico que supone a largo plazo. Se ha demostrado que la vacunación de adultos disminuye la morbilidad y la mortalidad asociadas a enfermedades infecciosas prevenibles, reduciendo las complicaciones y las hospitalizaciones, incluidos los ingresos a las unidades de cuidados intensivos. Hemos elaborado este documento de consenso con el objeto de diseñar un esquema de vacunación pragmático, accesible y estandarizado del adulto, según categoría de riesgo y edad, sobre la base de la evidencia disponible de vacunas accesibles y nuevas vacunas habiendo utilizado el Tercer Consenso de la Sociedad Paraguaya de Infectología del 2019 como base para las recomendaciones finales.


SUMMARY Vaccines prevent millions of deaths each year, and their efficacy and safety have been widely established. In economic terms, vaccination is one of the most cost-effective health interventions, generating significant savings and long-term economic growth. Adult vaccination has been shown to decrease morbidity and mortality associated with preventable Infectious diseases, reducing complications and hospitalizations, including admissions to intensive care units. We have prepared this consensus document in order to design a pragmatic, accessible and standardized vaccination scheme for adults, according to risk category and age, based on the available evidence of available vaccines and new vaccines, having used the third consensus of the Paraguayan Infectious Diseases Society of 2019 as a basis for the final recommendations.

2.
Arch. cardiol. Méx ; 77(supl.4): S4-77-S4-81, oct.-dic. 2007. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-568716

RESUMO

INTRODUCTION: The results presented in this study indicate that the immunosuppressor cyclosporine A acts as a cardioprotective drug. METHODS: This effect was analyzed during development of reperfusion-induced arrhythmias after 5 min period of coronary ligation in hearts of rats under anesthesia. RESULTS: The results indicate that cyclosporine inhibits Ca(2+)-induced mitochondrial damage; furthermore, when given before coronary occlusion, at a dose of 20 mg/kg, effectively protects against the high incidence of arrhythmias and the fall in blood pressure induced by reperfusion. In addition, it inhibits the delivery of lactic dehydrogenase and creatine kinase enzymes to the plasma. CONCLUSIONS: We propose that the protective effect could be related with its well documented action to restrain Ca(2+)-induced damage of mitochondrial functions.


Assuntos
Animais , Ratos , Ciclosporina , Imunossupressores , Traumatismo por Reperfusão Miocárdica , Ciclosporina , Imunossupressores , Mitocôndrias Cardíacas , Mitocôndrias Cardíacas , Permeabilidade , Ratos Wistar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA